Reliance Life Sciences Appoints Siva Sankar Mahamkali as VP of Biosimilars Manufacturing Operations

As global biosimilar pipelines push deeper into regulated markets, Reliance Life Sciences has appointed Siva Sankar Mahamkali as Vice President, Biosimilars Manufacturing Operations, a signal that the company is reinforcing its operational leadership ahead of what are likely to be increasingly demanding GMP and regulatory expectations in the US and EU export corridors.

Mahamkali brings more than two decades of experience in biologics and biosimilars manufacturing, with a track record spanning large-scale biopharmaceutical production and GMP operations. His appointment places a senior technical operator at the intersection of process validation, facility compliance, and the kind of cross-functional oversight that biosimilar programs require as they move from development into commercial-scale manufacturing.

For plant heads and QA directors in the Indian biosimilars space, the appointment reflects a broader industry pattern: as pipelines mature and export ambitions grow, companies are investing in manufacturing leadership with direct GMP and regulatory fluency rather than promoting from adjacent functions. The complexity of biosimilar comparability exercises, combined with tightening expectations under 21 CFR Part 211 and ICH Q10 quality system frameworks, makes that distinction operationally significant.

Reliance Life Sciences has been building its biologics portfolio with an eye on international markets, and the VP-level hire in manufacturing operations suggests the organization is aligning its quality and production infrastructure with the scrutiny that regulated-market submissions and pre-approval inspections will require. For QA leads, the relevant checkpoint is whether senior appointments of this kind are accompanied by corresponding investments in process validation programs and site readiness documentation.

Mahamkali's depth in large-scale biopharmaceutical manufacturing will be tested against the comparability and sterility assurance demands that define biosimilar regulatory packages in the EU and US, where agencies have raised the bar on manufacturing consistency data over the last several review cycles.

Source: Media4Growth via Indian Pharma Post, 21 May 2026.